Back

Lipid-lowering therapy use and LDL-C goal achievement in patients with hypercholesterolaemia or mixed dyslipidaemia in Hong Kong: findings from a retrospective database study

30 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering (3) Drug therapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Bryan Ping Yen Yan

The Chinese University of Hong Kong, Hong Kong (China)

5 More presentations in this session

Presentation thumbnail
Improving LDL-C goal attainment: real-world outcomes and the impact of guideline optimization
Doctor R. Rached (DK)
Abstract Slides Video
Presentation thumbnail
Statin-free PCSK9 inhibitor therapy versus high-intensity atorvastatin for primary prevention: a target trial emulation study
Associate Professor C. Hsu (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Achievement of LDL‑C targets in clinical practice in Spain: a comparison between Observatory II and Observatory I
Doctor J. Cosin Sales (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Evolocumab for high cardiovascular risk patients without previous stroke: a network meta-analysis of randomized controlled trials
Mr S. Phutinart (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Suboptimal LDL cholesterol target achievement in cardiac ATTR amyloidosis despite disease-modifying therapy
Doctor M. Pollak (Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid lowering (3)

The Event

Event poster

ESC Congress 2026

30 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Therapeutic gaps in low-density lipoprotein cholesterol management have narrowed over time but remain wide: a wide study of 40,141 acute coronary syndrome patients from 2016 to 2021
26 August 2023
thumbnail
Congress Presentation
Ai-THERO Study: a population-based analysis of patients at high or very high risk of atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels in Cantabria, Spain
30 August 2026
thumbnail
Congress Presentation
Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia
30 August 2026
thumbnail
Congress Presentation
Real-world use of bempedoic acid for ASCVD risk reduction in a rural UK primary care practice: Analysing trends in LDL-C reduction, adherence, and ESC target attainment
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources